Literature DB >> 19605773

Levetiracetam in nonconvulsive status epilepticus in a child with Angelman syndrome.

Peter Weber1.   

Abstract

Children with Angelman syndrome have an increased risk of developing a nonconvulsive status epilepticus. Although the urgency to treat nonconvulsive status epilepticus depends on the underlying illness, most clinicians and authors agree that treatment should be focused to rapidly terminate this condition. Until now, the use of levetiracetam to treat nonconvulsive status epilepticus in children is based only on some case reports. Our case further supports this treatment regime for a subgroup of children with a special risk of nonconvulsive status epilepticus and developmental delay.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19605773     DOI: 10.1177/0883073809338626

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  5 in total

1.  Levetiracetam for treatment of neonatal seizures.

Authors:  Nicholas S Abend; Ana M Gutierrez-Colina; Heather M Monk; Dennis J Dlugos; Robert R Clancy
Journal:  J Child Neurol       Date:  2011-01-13       Impact factor: 1.987

2.  Intravenous Levetiracetam for Treatment of Seizures in Term and Preterm Neonates.

Authors:  Pakize Karaoğlu; Semra Hız; Burçin İşcan; Ayşe I Polat; Müge Ayanoğlu; Nuray Duman; Uluç Yiş'
Journal:  J Pediatr Neurosci       Date:  2020-03-19

3.  Comparative Efficacy of IV Phenytoin, IV Valproate, and IV Levetiracetam in Childhood Status Epilepticus.

Authors:  Mudasir Nazir; Rayees Ahmad Tarray; Ravouf Asimi; Wajid Ali Syed
Journal:  J Epilepsy Res       Date:  2020-12-31

4.  Efficacy and tolerability of intravenous levetiracetam in childrens.

Authors:  Jose Aceves; Owais Khan; Diana Mungall; Ekokobe Fonkem; Chanin Wright; Andrea Wenner; Batool Kirmani
Journal:  Front Neurol       Date:  2013-08-14       Impact factor: 4.003

5.  A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel Ube3a mutants.

Authors:  Monica Sonzogni; Ilse Wallaard; Sara Silva Santos; Jenina Kingma; Dorine du Mee; Geeske M van Woerden; Ype Elgersma
Journal:  Mol Autism       Date:  2018-09-14       Impact factor: 7.509

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.